Sign In    Register

World Journal of Emergency Medicine ›› 2015, Vol. 6 ›› Issue (3): 165-171.doi: 10.5847/wjem.j.1920-8642.2015.03.001

• Meta-analyses •     Next Articles

Albuterol in the treatment of acute respiratory distress syndrome: A meta-analysis of randomized controlled trials

Ruo Wu1, Shi-yun Lin2, Hui-min Zhao1()   

  1. 1 Department of Emergency Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
    2 Department of Cardiology, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
  • Received:2015-03-06 Accepted:2015-07-12 Online:2015-09-15 Published:2015-09-15
  • Contact: Hui-min Zhao E-mail:hmzhao2006@163.com

Abstract:

BACKGROUND: This meta-analysis of randomized controlled trials aimed to systematically evaluate the value of albuterol in the treatment of patients with acute respiratory distress syndrome (ARDS).
DATA SOURCES: Randomized controlled trials on albuterol treatment of ARDS from its inception to October 2014 were searched systematically. The databases searched included: PubMed, Ovid EMBASE, Ovid Cochrane, CNKI, WANFANG and VIP. The trials were screened according to the pre-designed inclusion and exclusion criteria. We performed a systematic review and meta-analysis of the randomized controlled trials (RCTs) on albuterol treatment, attempting to improve outcomes, i.e. lowering the 28-day mortality and ventilator-free days.
RESULTS: Three RCTs involving 646 patients met the inclusion criteria. There was no significant decrease in the 28-day mortality (risk difference=0.09; P=0.07, P for heterogeneity=0.22, I2=33%). The ventilator-free days and organ failure-free days were significantly lower in the patients who received albuterol (mean difference=-2.20; P<0.001, Pfor heterogeneity=0.49, I2=0% and mean difference=-1.71, P<0.001, P for heterogeneity=0.60, I2=0%).
CONCLUSIONS: Current evidences indicate that treatment with albuterol in the early course of ARDS was not effective in increasing the survival, but significantly decreasing the ventilator-free days and organ failure-free days. Owing to the limited number of included trails, strong recommendations cannot be made.

Key words: Albuterol, Acute respiratory distress syndrome, Mortality, Ventilator-free days